Skip to main content

Ontario Funds High Impact Clinical Trials with $12.7M

NEW YORK (GenomeWeb News) – The Ontario Institute for Cancer Research has been awarded C$12.6 million (US$12.7 million) from the provincial government to fund a clinical trials program that will use genomics and personalized medicine in a translational science effort, OICR said Monday.

The funding will be used to support two trials that are part of the High Impact Clinical Trials (HICT) Program over a four-year period.

One of these HICT efforts is the Genomic Cohort Study for Ontario Clinical Trials, which is a collaboration with Princess Margaret Hospital. In this study, researchers will develop standard operating procedures to help safely and effectively integrate genomics technologies with standard clinical practice and to improve patient care. The expectation is that genetic information could be used to help determine how to best match patients to the most optimal treatments to maximize the anti-tumor efficacy and to reduce side-effects.

The other clinical trial is the Rare Tumor Clinical Trials Initiative, a partnership between OICR, Pfizer Canada, and the NCIC Clinical Trials Group at Queens University. This multidisciplinary and multi-center trial will engage genomics researchers and pathologists to develop new ways to study rare tumors.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.